LeMaitre Vascular, Inc.
Description
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
About
CEO
Mr. George W. LeMaitre
Employees
614
Instrument type
Common Stock
Sector
Healthcare
Industry
Medical Instruments & Supplies
MIC code
XNMS
Address
63 Second Avenue, Burlington, MA 01803, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 29, 2025 | — | — | — | — |
| Jul 30, 2025 | — | — | — | — |
| Apr 30, 2025 | — | — | — | — |
| Feb 26, 2025 | 0.49 | — | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 7 | — | 8 |
| Average estimate | — | 0.51 | — | 2.16 |
| Low estimate | — | 0.47 | — | 2.06 |
| High estimate | — | 0.56 | — | 2.36 |
| Last year EPS | — | 0.44 | — | 1.94 |
[stock_revenue_estimate]
Growth estimates
Current qtr
29.610%
Next qtr. (Mar 2025)
15.260%
Current year
44.780%
Next year (Dec 2025)
11.280%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 193.48M | 161.65M | 154.42M | 129.37M | 117.23M |
| Cost of revenue | 66.44M | 56.76M | 53.04M | 44.75M | 37.38M |
| Gross profit | 127.05M | 104.90M | 101.38M | 84.62M | 79.85M |
| Operating expense | |||||
| Research & development | 16.97M | 13.29M | 11.80M | 10.10M | 9.28M |
| Selling general and admin | 72.89M | 61.67M | 53.16M | 46.20M | 49.39M |
| Other operating expenses | — | — | — | — | — |
| Operating income | 37.20M | 29.94M | 36.43M | 28.32M | 21.18M |
| Non operating interest income | |||||
| Income | 3.08M | 986,000 | 197,000 | 207,000 | 698,000 |
| Expense | — | — | 2.22M | 1.31M | — |
| Other income expense | -799,000 | -3.43M | -116,000 | 141,000 | -202,000 |
| Pretax income | 39.48M | 27.49M | 34.29M | 27.36M | 21.68M |
| Tax provision | 9.37M | 6.85M | 7.38M | 6.14M | 3.75M |
| Net income | 30.11M | 20.64M | 26.91M | 21.22M | 17.93M |
| Basic EPS | 1.36 | 0.94 | 1.27 | 1.05 | 0.91 |
| Diluted EPS | 1.34 | 0.93 | 1.25 | 1.04 | 0.88 |
| Basic average shares | 22.22M | 21.98M | 21.16M | 20.25M | 19.81M |
| Diluted average shares | 22.22M | 21.98M | 21.16M | 20.25M | 19.81M |
| EBITDA | 49.48M | 40.03M | 47.58M | 36.59M | 27.30M |
| Net income from continuing op. | 30.11M | 20.64M | 26.91M | 21.22M | 17.93M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 346.78M | 310.48M | 292.80M | 252.81M | 188.34M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 24.27M | 19.13M | 13.86M | 26.76M | 11.79M |
| Other short term investments | 80.81M | 63.56M | 56.10M | 214,000 | 20.90M |
| Accounts receivable | 25.06M | 22.04M | 19.63M | 19.55M | 16.57M |
| Other receivables | — | — | — | — | — |
| Inventory | 52.33M | 45.28M | 40.65M | 39.17M | 34.63M |
| Prepaid assets | — | — | 4.19M | 2.62M | 3.31M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 6.38M | 6.73M | 4.19M | 2.62M | 3.31M |
| Non current assets | |||||
| Properties | 39.01M | 30.87M | 30.96M | 28.88M | 26.97M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 22.26M | 27.79M | 24.11M | 22.31M | 20.87M |
| Construction in progress | — | — | — | — | — |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -21.49M | -25.12M | -22.93M | -20.09M | -17.77M |
| Goodwill | 173.60M | 178.42M | 184.60M | 190.80M | 104.80M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 41.71M | 46.53M | 52.71M | 58.91M | 24.89M |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 4.74M | 2.74M | 2.13M | 2.60M | 1.34M |
| Total liabilities | 48.88M | 42.28M | 38.65M | 80.24M | 40.20M |
| Current liabilities | |||||
| Accounts payable | 3.73M | 2.90M | 2.34M | 2.39M | 2.60M |
| Accrued expenses | 9.91M | 8.75M | 5.55M | 6.46M | 4.46M |
| Short term debt | 2.47M | 1.89M | 1.87M | 4.45M | 1.76M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | 13.74M | 11.22M | 10.79M | 11.07M | 9.55M |
| Pensions | — | 10.77M | 10.24M | 8.68M | 8.55M |
| Other current liabilities | 24,000 | 573,000 | 1.27M | 772,000 | 2.48M |
| Non current liabilities | |||||
| Long term debt | 16.62M | 14.71M | 14.07M | 50.32M | 13.96M |
| Provision for risks and charges | 637,000 | 636,000 | 799,000 | 813,000 | 781,000 |
| Deferred liabilities | 107,000 | 69,000 | 70,000 | 127,000 | 1.18M |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 1.63M | 1.53M | 1.90M | 3.83M | 3.43M |
| Shareholders equity | |||||
| Common stock | 239,000 | 237,000 | 235,000 | 221,000 | 217,000 |
| Retained earnings | 115.43M | 97.77M | 88.13M | 70.55M | 57.03M |
| Other shareholders equity | -4.63M | -6.03M | -3.44M | -1.53M | -4.01M |
| Total shareholders equity | 297.90M | 268.20M | 254.15M | 172.57M | 148.14M |
| Additional paid in capital | 200.76M | 189.27M | 181.63M | 114.92M | 105.93M |
| Treasury stock | 13.90M | 13.05M | 12.40M | 11.60M | 11.03M |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||
| Net Income | 30.11M | 20.64M | 26.91M | 21.22M | 17.93M | 22.94M | 17.18M | 10.59M | 7.76M | 3.92M | 3.20M | 2.57M | 2.14M | 6.01M | 1.60M | -3.31M | -2.93M | -1.17M | 55,000 | 927,000 |
| Depreciation | 9.52M | 9.43M | 11.07M | 8.40M | 5.42M | 4.32M | 4.06M | 3.59M | 3.39M | 3.33M | 2.79M | 2.23M | 2.04M | 1.38M | 1.42M | 1.59M | 1.39M | 1.31M | 1.21M | 967,000 |
| Deferred Taxes | 783,000 | -182,000 | 79,000 | -328,000 | 824,000 | -2.15M | 300,000 | 140,000 | -384,000 | -72,000 | 287,000 | 287,000 | 1.16M | -2.38M | 224,000 | 249,000 | 639,000 | -6,000 | 182,000 | — |
| Stock-Based Compensation | 5.32M | 4.17M | 3.48M | 3.02M | 2.64M | 2.35M | 2.26M | 1.68M | 1.42M | 1.30M | 1.25M | 1.21M | 1.10M | 967,000 | 985,000 | 801,000 | — | — | — | — |
| Other Non-Cash Items | -78,000 | -108,000 | -674,000 | 182,000 | 171,000 | -29,000 | 106,000 | — | — | 138,000 | 57,000 | — | 732,000 | 108,000 | 729,000 | 1.08M | 1.05M | 481,000 | 33,000 | 331,000 |
| Accounts Receivable | -3.14M | -3.53M | -818,000 | -939,000 | -1.30M | -1.28M | -1.51M | -922,000 | -1.88M | -654,000 | -1.25M | -640,000 | -174,000 | -972,000 | -486,000 | -353,000 | -1.68M | -689,000 | -388,000 | -727,000 |
| Accounts Payable | 4.60M | 645,000 | -1.73M | 4.32M | -596,000 | 4.31M | 1.52M | -103,000 | 2.62M | -1.09M | 861,000 | 1.36M | -3.17M | 3.13M | — | — | — | — | — | — |
| Other Assets & Liabilities | -9.79M | -7.42M | -5.49M | -2.61M | -11.34M | -4.26M | -1.35M | -134,000 | 608,000 | -2.71M | -2.17M | -3.73M | -998,000 | -1.74M | 164,000 | 1.47M | -1.80M | -780,000 | -1.77M | 167,000 |
| Operating Cash Flow | 37.31M | 23.65M | 32.82M | 33.27M | 13.76M | 26.20M | 22.56M | 14.84M | 13.54M | 4.17M | 5.04M | 3.30M | 2.83M | 6.50M | 4.63M | 1.52M | -3.34M | -858,000 | -679,000 | 1.67M |
| Investing Activities | ||||||||||||||||||||
| Capital Expenditures | -7.27M | -2.37M | -4.88M | -959,000 | -3.76M | -3.05M | -6.42M | -2.84M | -2.26M | -1.17M | -2.73M | -1.21M | -2.02M | -2.47M | -577,000 | -624,000 | -1.39M | -935,000 | -526,000 | -1.56M |
| Net Intangibles | — | — | — | — | — | — | — | -2,000 | -17,000 | -15,000 | -164,000 | -116,000 | -64,000 | -87,000 | -1.05M | -114,000 | — | — | — | — |
| Net Acquisitions | -899,000 | — | — | -72.63M | -21.24M | -4.88M | — | -14.37M | -1.21M | -6.56M | -3.29M | -3.87M | 263,000 | -3.48M | -759,000 | -835,000 | -5.11M | — | -1.38M | -500,000 |
| Purchase of Investments | -16.55M | -8.00M | -59.19M | -2.21M | -22.70M | -19.62M | -22.54M | — | — | — | — | — | — | — | — | -4.32M | -12.09M | -15.69M | — | -300,000 |
| Sale of Investments | — | — | 3.00M | 22.90M | 23.60M | 20.50M | — | — | — | — | — | — | — | 803,000 | 4.57M | 14.91M | 9.40M | 295,000 | 300,000 | — |
| Investing Cash Flow | -24.72M | -10.37M | -61.08M | -52.89M | -24.10M | -7.06M | -28.96M | -17.21M | -3.46M | -7.73M | -6.02M | -5.08M | -1.76M | -5.11M | 3.23M | 9.13M | -9.19M | -15.93M | -1.38M | -2.91M |
| Financing Activities | ||||||||||||||||||||
| Long-Term Debt Issuance | — | — | — | 40.00M | — | — | — | — | — | — | — | — | — | — | 108,000 | — | — | — | — | — |
| Long-Term Debt Payments | — | — | -39.00M | -26.00M | — | — | — | — | — | -1.13M | — | — | -469,000 | -21,000 | — | -262,000 | — | — | — | — |
| Other Financing Charges | — | -1.07M | -401,000 | -4.55M | -2.06M | -1.20M | -463,000 | -385,000 | -646,000 | -520,000 | 31,000 | 23,000 | 50,000 | 70,000 | — | — | -121,000 | -2.65M | 3,000 | -11,000 |
| Financing Cash Flow | -6.28M | -9.23M | 13.70M | 7.16M | -4.62M | -4.42M | 80,000 | -2.58M | 1.08M | 6.66M | -961,000 | -3.16M | -3.80M | -2.34M | -376,000 | -286,000 | 42,000 | 33.05M | 2.56M | 2.12M |
| Other Cash Details | ||||||||||||||||||||
| End Cash Position | 24.27M | 19.13M | 13.86M | 26.76M | 11.79M | 26.32M | 19.10M | 24.29M | 27.45M | 18.69M | 14.71M | 16.45M | 20.13M | 22.61M | 23.19M | 15.90M | 6.69M | 15.39M | 817,000 | 724,000 |
| Income Tax Paid | 7.55M | 8.34M | 10.15M | 4.47M | — | 5.52M | 3.15M | 4.23M | 4.79M | 2.09M | 1.02M | 544,000 | 717,000 | 835,000 | — | — | — | — | — | — |
| Interest Paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 29.49M | 22.15M | 30.22M | 31.82M | 10.42M | 16.45M | 16.45M | 14.05M | 9.15M | 4.32M | 2.49M | 3.40M | 1.09M | 4.49M | 3.82M | -157,000 | -3.22M | -1.50M | -2.22M | 119,000 |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Conestoga Small Cap Fund | Sep 30, 2024 | 1,420,521 | 139.96M | 6.32% |
| iShares Core S&P Smallcap ETF | Nov 30, 2024 | 1,322,790 | 130.33M | 5.88% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 626,683 | 61.75M | 2.79% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 566,537 | 55.82M | 2.52% |
| Professionally Managed Portf-Congress Small Cap Growth Fd | Nov 30, 2024 | 400,000 | 39.41M | 1.78% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 311,152 | 30.66M | 1.38% |
| Nationwide Geneva Small Cap Growth Fd | Oct 31, 2024 | 294,447 | 29.01M | 1.31% |
| Price (T.Rowe) Integrated U.S. Small-Cap Growth Equity Fd | Sep 30, 2024 | 211,096 | 20.80M | 0.94% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 208,324 | 20.53M | 0.93% |
| BlackRock Advantage Small Cap Core Fund | Nov 30, 2024 | 199,112 | 19.62M | 0.89% |
Article
LeMaitre Will Announce Fourth Quarter 2024 Earnings Results February 27, 2025
BURLINGTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2024 financial results on Thursday, February 27, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.
Jan 27, 2025
Article
The Most Underrated Mistake Destroying Your Retirement - December Dividend Income Report
Since its inception, my portfolio has been up 177%, with a 15% annualized growth rate. At this time, I'm thinking of adding a little bit more of Telus to this portfolio. The stock has been significantly penalized, while Telus' situation isn't that catastrophic (free cash flow and cash from operations improved throughout 2024). After selling Texas Instruments, the only stock I could see myself selling in 2025 would be BlackRock.
Jan 27, 2025
Video
Julie Biel shares her 2025 small cap picks
CNBC guest trader Julie Biel shares her 2025 small cap picks.
Dec 26, 2024
